ROS stress in cancer cells and therapeutic implications
2004 · Drug Resistance Updates · 1,934 citations
https://doi.org/10.1016/j.drup.2004.01.004
D
Dennis Carney
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
81
Papers
4.4K
Citations
22
h-index
37
i10-index
Dennis Carney is an academic researcher from Peter MacCallum Cancer Centre. The author has contributed to research in topics: Chronic Lymphocytic Leukemia Research & Lymphoma Diagnosis and Treatment & Immunodeficiency and Autoimmune Disorders. The author has an h-index of 22, co-authored 69 publications.
ORCID: 0000-0003-3239-6065Papers by this author
worksDetection of NPM1 exon 12 mutations and FLT3 – internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia
2008 · Journal of Hematology & Oncology · 49 citations
https://doi.org/10.1186/1756-8722-1-10
Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial
2024 · The Lancet Haematology · 9 citations
https://doi.org/10.1016/s2352-3026(24)00317-x
Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study
2024 · Clinical Lymphoma Myeloma & Leukemia · 2 citations
https://doi.org/10.1016/s2152-2650(24)00564-0
CLL-057 Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study
2024 · Clinical Lymphoma Myeloma & Leukemia · 1 citations
https://doi.org/10.1016/s2152-2650(24)01258-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat